Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.41 |
| ▸ | GLS | O94925 | 1/20 | 0.40 |
| ▸ | PPARG | P37231 | 5/20 | 0.40 |
| ▸ | ABL1 | P00519 | 2/20 | 0.40 |
| ▸ | IDE | P14735 | 2/20 | 0.40 |
| ▸ | RIN1 | Q13671 | 2/20 | 0.40 |
| ▸ | NR2E3 | Q9Y5X4 | 1/20 | 0.40 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.40 |
| ▸ | PTPN1 | P18031 | 4/20 | 0.37 |
| ▸ | ACP1 | P24666 | 2/20 | 0.37 |
| ▸ | CDC25B | P30305 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | TSHR | P16473 | 4/20 | 0.35 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.35 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.35 |
| ▸ | GPR84 | Q9NQS5 | 4/20 | 0.35 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.35 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.35 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.35 |
| ▸ | NSD2 | O96028 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11191261 | 0.98 | PPARG (0.42) | TDP1GLSPPARGABL1IDE | |
| SCHEMBL3587679 | 0.81 | TSHR (0.40) | TDP1GLSPPARGNR2E3NCOR2 | |
| SCHEMBL200462 | 0.79 | GLS (0.47) | GLSTSHRKMT2A | |
| SCHEMBL1005092 | 0.79 | GLS (0.47) | GLSTSHRKMT2A | |
| SCHEMBL8775616 | 0.77 | PTPN1 (0.44) | GLSPTPN1ACP1CDC25B | |
| SCHEMBL8775465 | 0.77 | PTPN1 (0.44) | GLSPTPN1ACP1CDC25B | |
| SCHEMBL8775455 | 0.77 | PTPN1 (0.44) | GLSPTPN1ACP1CDC25B | |
| SCHEMBL8396727 | 0.75 | MAPT (0.35) | GLSHDAC11 | |
| SCHEMBL2158180 | 0.74 | GLS (0.40) | GLSL3MBTL1 | |
| SCHEMBL9460988 | 0.73 | GLS (0.46) | GLS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100113504-A1 | AMIDE COMPOUNDS AND THEIR USE AS ANTITUMOR AGENTS | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2010-05-06 | — | — | US | disclosed |
| US-20100113504-A1 | AMIDE COMPOUNDS AND THEIR USE AS ANTITUMOR AGENTS | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2010-05-06 | — | — | US | disclosed |
| US-20100113504-A1 | AMIDE COMPOUNDS AND THEIR USE AS ANTITUMOR AGENTS | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2010-05-06 | — | — | US | disclosed |
| CN-101641341-A | Amide compounds and their use as antitumor agents | SIGMA TAU IND FARMACEUTI IT | 2010-02-03 | — | — | CN | disclosed |
| EP-2137169-A1 | AMIDE COMPOUNDS AND THEIR USE AS ANTITUMOR AGENTS | SIGMA-TAU Industrie Farmaceutiche Riunite S.p.A. (IT) | 2009-12-30 | — | — | EP | disclosed |
| WO-2008110583-A1 | AMIDE COMPOUNDS AND THEIR USE AS ANTITUMOR AGENTS | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2008-09-18 | — | — | WO | disclosed |
| WO-2008110583-A1 | AMIDE COMPOUNDS AND THEIR USE AS ANTITUMOR AGENTS | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2008-09-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100113504-A1 | AMIDE COMPOUNDS AND THEIR USE AS ANTITUMOR AGENTS | HDAC3, HCCS, CCNH | TDP1 4833/4885GLS 431/4885PPARG 1330/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.